Bukwang Pharm signs exclusive sales agreement of schizophrenia treatment ‘lurasidone’
Bukwang Pharm announced it signed an exclusive license agreement od development, marketing, sales and distribution in Korea for ‘lurasidone’ developed by Sumitomo Dainippon Pharma for the indication of schizophrenia and bipolar disorder.
Lurasidone, an atypical schizophrenia treatment, works as ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
